Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
01 Agosto 2023 - 5:05PM
Business Wire
Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology
company, today announced an agreement with Illumina Inc. (NASDAQ:
ILMN), a global leader in DNA sequencing and array-based
technologies, that resolves their pending litigation and promotes a
shared resolution to advance the companies’ long-term, commercial
partnership.
The three-year agreement includes a joint request to dismiss
with prejudice the pending litigation between the companies,
including any allegations related to the subject intellectual
property. The companies have also extended their long-standing
commercial relationship by agreeing to collaborate on the sharing
of specimen samples to advance cancer research, and by entering
into a new long-term purchase and supply commitment.
“Both companies are deeply committed to our collaboration to
help patients and conquer cancer,” said Chris Freeman, chief
commercial officer of Guardant. “This agreement supports getting
our transformative technologies to even more patients globally,
while strengthening our long-standing and valued partnership with
Illumina.”
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY™ tests for advanced-stage cancer patients, and
Guardant Reveal™ for early-stage cancer patients. The Guardant
Health screening portfolio, including the commercially launched
Shield™ test, aims to address the needs of individuals eligible for
cancer screening. For more information, visit guardanthealth.com
and follow the company on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230801582479/en/
Investors: Carrie Mendivil
investors@guardanthealth.com
Media: Matt Burns 518-423-5907
press@guardanthealth.com
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
